AMRX saw its Momentum Indicator move above the 0 level on November 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 72 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 85%.
The Moving Average Convergence Divergence (MACD) for AMRX just turned positive on November 11, 2026. Looking at past instances where AMRX's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.
Following a +2.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRX advanced for three days, in 245 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 217 of 265 cases where AMRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
The 10-day RSI Indicator for AMRX moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 35 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
AMRX broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. AMRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AMRX's P/B Ratio (212.412) is very high in comparison to the industry average of (6.379). P/E Ratio (40.280) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (1.947) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.899) is also within normal values, averaging (183.387).
EBS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 03, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 44 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EBS as a result. In 79 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
EBS moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for EBS crossed bearishly below the 50-day moving average on November 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EBS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for EBS entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +4.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where EBS advanced for three days, in 214 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.910) is normal, around the industry mean (6.379). P/E Ratio (-1.782) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.160) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.493) is also within normal values, averaging (183.387).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. EBS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EBS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
AMRX | EBS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 87 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 39 Fair valued | |
PROFIT vs RISK RATING 1..100 | 4 | 100 | |
SMR RATING 1..100 | 99 | 97 | |
PRICE GROWTH RATING 1..100 | 36 | 62 | |
P/E GROWTH RATING 1..100 | 97 | 98 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EBS's Valuation (39) in the Biotechnology industry is somewhat better than the same rating for AMRX (100) in the Pharmaceuticals Major industry. This means that EBS’s stock grew somewhat faster than AMRX’s over the last 12 months.
AMRX's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is significantly better than the same rating for EBS (100) in the Biotechnology industry. This means that AMRX’s stock grew significantly faster than EBS’s over the last 12 months.
EBS's SMR Rating (97) in the Biotechnology industry is in the same range as AMRX (99) in the Pharmaceuticals Major industry. This means that EBS’s stock grew similarly to AMRX’s over the last 12 months.
AMRX's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as EBS (62) in the Biotechnology industry. This means that AMRX’s stock grew similarly to EBS’s over the last 12 months.
AMRX's P/E Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as EBS (98) in the Biotechnology industry. This means that AMRX’s stock grew similarly to EBS’s over the last 12 months.
| AMRX | EBS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 78% | N/A |
| Stochastic ODDS (%) | 2 days ago 76% | 2 days ago 78% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 66% | 2 days ago 88% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 87% |
| Advances ODDS (%) | 7 days ago 83% | 9 days ago 80% |
| Declines ODDS (%) | 2 days ago 68% | 5 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 69% | N/A |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 86% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMRX’s FA Score shows that 1 FA rating(s) are green while EBS’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMRX’s TA Score shows that 4 TA indicator(s) are bullish while EBS’s TA Score has 2 bullish TA indicator(s).
AMRX (@Pharmaceuticals: Generic) experienced а -0.23% price change this week, while EBS (@Pharmaceuticals: Generic) price change was -4.75% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.48%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -7.77%.
AMRX is expected to report earnings on Feb 26, 2027.
EBS is expected to report earnings on Mar 03, 2027.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
A.I.dvisor indicates that over the last year, AMRX has been loosely correlated with VTRS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRX jumps, then VTRS could also see price increases.
| Ticker / NAME | Correlation To AMRX | 1D Price Change % | ||
|---|---|---|---|---|
| AMRX | 100% | -0.70% | ||
| VTRS - AMRX | 46% Loosely correlated | -0.38% | ||
| AMPH - AMRX | 46% Loosely correlated | -0.68% | ||
| ANIP - AMRX | 39% Loosely correlated | -0.77% | ||
| TEVA - AMRX | 38% Loosely correlated | -4.34% | ||
| SUPN - AMRX | 37% Loosely correlated | -2.99% | ||
More | ||||
A.I.dvisor indicates that over the last year, EBS has been loosely correlated with AMPH. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then AMPH could also see price increases.
| Ticker / NAME | Correlation To EBS | 1D Price Change % | ||
|---|---|---|---|---|
| EBS | 100% | +0.35% | ||
| AMPH - EBS | 41% Loosely correlated | -0.68% | ||
| SIGA - EBS | 40% Loosely correlated | +4.01% | ||
| COLL - EBS | 40% Loosely correlated | +0.43% | ||
| XERS - EBS | 33% Loosely correlated | +0.24% | ||
| AMRX - EBS | 32% Poorly correlated | -0.70% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AVSF | 45.66 | 0.05 | +0.11% |
| Avantis Short-Term Fixed Income ETF (AVSF) | |||
| PMDE | 26.32 | -0.12 | -0.45% |
| PGIM S&P 500 Max Buffer ETF - December (PMDE) | |||
| DFSV | 38.70 | -0.39 | -1.00% |
| U.S. Small Cap Value Portfolio: ETF Class Shares (DFSV) | |||
| MQQQ | 189.40 | -11.06 | -5.52% |
| Tradr 2X Long Innovation 100 Monthly ETF (MQQQ) | |||
| NODE | 27.36 | -1.76 | -6.04% |
| VanEck Onchain Economy ETF (NODE) | |||